Higher dose offers new hope for psoriasis patients who stopped responding to standard therapy

NCT ID NCT01680159

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis who had initially improved on the standard dose of Remicade but later lost that benefit. The goal was to see if the increased dose could again reduce skin symptoms. Participants were monitored for safety and how well their psoriasis cleared up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exfoliative dermatitis psoriasis psoriatic arthritis pustular psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS PSORIATIC ARTHRITIS PSORIATIC ERYTHRODERMA PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED)

Contacts and locations

Show contact details

Locations

Investigational site

Chugoku, Japan
Investigational site

Chūbu, Japan
Investigational site

Hokkaido, Japan
Investigational site

Kanto, Japan
Investigational site

Kinki, Japan
Investigational site

Kyushu, Japan
Investigational site

Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.